Cargando…
Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway
Despite the increase in the global prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD), no approved drug currently exists for the disease. Poria cocos (Schw.) Wolf (P. cocos) is a medicinal mushroom belonging to a family of polyporaceae widely used in TCM clinics to protect th...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581278/ https://www.ncbi.nlm.nih.gov/pubmed/36278226 http://dx.doi.org/10.3389/fphar.2022.1007274 |
_version_ | 1784812586660790272 |
---|---|
author | He, Jinbiao Yang, Yu Zhang, Fan Li, Yanjuan Li, Xiaosi Pu, Xuemei He, Xudong Zhang, Mei Yang, Xinxing Yu, Qiuman Qi, Yan Li, Xuefang Yu, Jie |
author_facet | He, Jinbiao Yang, Yu Zhang, Fan Li, Yanjuan Li, Xiaosi Pu, Xuemei He, Xudong Zhang, Mei Yang, Xinxing Yu, Qiuman Qi, Yan Li, Xuefang Yu, Jie |
author_sort | He, Jinbiao |
collection | PubMed |
description | Despite the increase in the global prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD), no approved drug currently exists for the disease. Poria cocos (Schw.) Wolf (P. cocos) is a medicinal mushroom belonging to a family of polyporaceae widely used in TCM clinics to protect the liver and treat obesity. However, its efficacy, practical components, and underlying mechanism against MAFLD are yet to be determined. In this study, we evaluated the effects of Poria cocos (P. cocos) ethanol extract (EPC) on hepatic dyslipidemia, steatosis, and inflammation by both bioinformatics analysis and MAFLD rats induced by HFD feeding. We found EPC treatment dramatically reduced lipid accumulation, inflammatory cell infiltration, and liver injury. EPC reduced serum TC, TG levels, and hepatic TG, TBA, and NEFA contents. UHPLC Q-Trap/MS examination of BA profiles in serum and feces showed that EPC increased fecal conjugated BAs, decreased free BAs, and improved BA metabolism in HFD-fed rats. Western blot and RT-qPCR analysis showed that EPC could activate hepatic FXR and PPARα expression and reduce CYP7A1 and SREBP-1c expression. Systemic pharmacology combined with molecular docking suggested that poricoic acid B and polyporenic acid C, the major active compounds in EPC, could ameliorate lipid homeostasis by activating the nuclear receptor PPARα. We further confirmed their inhibition effects of lipid droplet deposition in steatized L-02 hepatocytes. In summary, EPC alleviated HFD-induced MAFLD by regulating lipid homeostasis and BA metabolism via the FXR/PPARα-SREBPs signaling pathway. P. cocos triterpenes, such as poricoic acid B and polyporenic acid C, were the characteristic substances of P. cocos for the treatment of MAFLD. |
format | Online Article Text |
id | pubmed-9581278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95812782022-10-20 Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway He, Jinbiao Yang, Yu Zhang, Fan Li, Yanjuan Li, Xiaosi Pu, Xuemei He, Xudong Zhang, Mei Yang, Xinxing Yu, Qiuman Qi, Yan Li, Xuefang Yu, Jie Front Pharmacol Pharmacology Despite the increase in the global prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD), no approved drug currently exists for the disease. Poria cocos (Schw.) Wolf (P. cocos) is a medicinal mushroom belonging to a family of polyporaceae widely used in TCM clinics to protect the liver and treat obesity. However, its efficacy, practical components, and underlying mechanism against MAFLD are yet to be determined. In this study, we evaluated the effects of Poria cocos (P. cocos) ethanol extract (EPC) on hepatic dyslipidemia, steatosis, and inflammation by both bioinformatics analysis and MAFLD rats induced by HFD feeding. We found EPC treatment dramatically reduced lipid accumulation, inflammatory cell infiltration, and liver injury. EPC reduced serum TC, TG levels, and hepatic TG, TBA, and NEFA contents. UHPLC Q-Trap/MS examination of BA profiles in serum and feces showed that EPC increased fecal conjugated BAs, decreased free BAs, and improved BA metabolism in HFD-fed rats. Western blot and RT-qPCR analysis showed that EPC could activate hepatic FXR and PPARα expression and reduce CYP7A1 and SREBP-1c expression. Systemic pharmacology combined with molecular docking suggested that poricoic acid B and polyporenic acid C, the major active compounds in EPC, could ameliorate lipid homeostasis by activating the nuclear receptor PPARα. We further confirmed their inhibition effects of lipid droplet deposition in steatized L-02 hepatocytes. In summary, EPC alleviated HFD-induced MAFLD by regulating lipid homeostasis and BA metabolism via the FXR/PPARα-SREBPs signaling pathway. P. cocos triterpenes, such as poricoic acid B and polyporenic acid C, were the characteristic substances of P. cocos for the treatment of MAFLD. Frontiers Media S.A. 2022-10-05 /pmc/articles/PMC9581278/ /pubmed/36278226 http://dx.doi.org/10.3389/fphar.2022.1007274 Text en Copyright © 2022 He, Yang, Zhang, Li, Li, Pu, He, Zhang, Yang, Yu, Qi, Li and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology He, Jinbiao Yang, Yu Zhang, Fan Li, Yanjuan Li, Xiaosi Pu, Xuemei He, Xudong Zhang, Mei Yang, Xinxing Yu, Qiuman Qi, Yan Li, Xuefang Yu, Jie Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway |
title | Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway |
title_full | Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway |
title_fullStr | Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway |
title_full_unstemmed | Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway |
title_short | Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR/PPARα-SREBPs pathway |
title_sort | effects of poria cocos extract on metabolic dysfunction-associated fatty liver disease via the fxr/pparα-srebps pathway |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581278/ https://www.ncbi.nlm.nih.gov/pubmed/36278226 http://dx.doi.org/10.3389/fphar.2022.1007274 |
work_keys_str_mv | AT hejinbiao effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT yangyu effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT zhangfan effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT liyanjuan effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT lixiaosi effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT puxuemei effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT hexudong effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT zhangmei effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT yangxinxing effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT yuqiuman effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT qiyan effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT lixuefang effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway AT yujie effectsofporiacocosextractonmetabolicdysfunctionassociatedfattyliverdiseaseviathefxrpparasrebpspathway |